Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective and randomized controlled study on the efficacy and safety of ipragliflozin and metformin to visceral fat reduction for the patients being treated with DPP-4 inhibitors for poor glycemic controlled type-2 diabetes

Trial Profile

Prospective and randomized controlled study on the efficacy and safety of ipragliflozin and metformin to visceral fat reduction for the patients being treated with DPP-4 inhibitors for poor glycemic controlled type-2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipragliflozin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms PRIME-V
  • Most Recent Events

    • 05 Oct 2018 Results comparing ipragliflozin and metformin for bone density and muscle in type 2 diabetes patients, presented at the 54th Annual Meeting of the European Association for the Study of Diabetes.
    • 05 Oct 2018 Results of a sun-analysis (n=14) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 26 Jun 2018 Primary endpoint has been met. (The change rate of the visceral fat area by CT after 24 weeks therapy in the two groups) as per results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top